KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Gross Margin (2016 - 2023)

TherapeuticsMD's Gross Margin history spans 13 years, with the latest figure at 100.0% for Q4 2023.

  • For Q4 2023, Gross Margin changed 0.0% year-over-year to 100.0%; the TTM value through Dec 2023 reached 92.47%, down 2622.0%, while the annual FY2023 figure was 100.0%, 200.0% up from the prior year.
  • Gross Margin reached 100.0% in Q4 2023 per TXMD's latest filing, up from 100.0% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 2082.45% in Q1 2022 to a low of 100.0% in Q3 2023.
  • Average Gross Margin over 5 years is 184.76%, with a median of 81.28% recorded in 2019.
  • Peak YoY movement for Gross Margin: skyrocketed 200604bps in 2022, then plummeted -198245bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 81.9% in 2019, then dropped by -8bps to 75.28% in 2020, then decreased by -1bps to 74.64% in 2021, then skyrocketed by 34bps to 100.0% in 2022, then changed by 0bps to 100.0% in 2023.
  • Per Business Quant, the three most recent readings for TXMD's Gross Margin are 100.0% (Q4 2023), 100.0% (Q3 2023), and 100.0% (Q2 2023).